Aspira Women's Health, Inc. (AWH)
Stock Price:
$4.05 USD
0.34 (9.16%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
394.38M |
| Revenue (ttm) |
4.96M |
| Net Income (ttm) |
-15.23M |
| Shares Out |
100.19M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$4.05 |
| Previous Close |
$3.71 |
| Change ($) |
0.34 |
| Change (%) |
9.16% |
| Day's Open |
3.77 |
| Day's Range |
3.74 - 4.34 |
| Day's Volume |
976,067 |
| 52-Week Range |
0.35 - 5.78 |
More Stats
| Market Cap |
394.38M |
| Enterprise Value |
387.49M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
100.19M |
| Float |
52.24M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-0.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.28M |
| Short Ratio |
4.21 |
| Short % of Float |
4.63% |
| Beta |
3.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
79.59 |
| PB Ratio |
87.11 |
| Revenue |
4.96M |
| Operating Income |
-15.36M |
| Net Income |
-15.23M |
| Free Cash Flow |
-13.47M |
| Net Cash |
6.89M |
| Net Cash / Share |
0.07 |
| Gross Margin |
24.12% |
| Operating Margin |
-309.97% |
| Profit Margin |
-307.30% |
| FCF Margin |
-271.77% |
| ROA |
-103.18% |
| ROE |
-340.69% |
| ROIC |
3,863.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1.00
Current: 4.05
High
1.00
Target: 1.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 4.54 | 3.05 | 3.12 | 2.64 | 2.18 | 2.52 | 2.57 | 2.09 | 1.92 | 1.18 |
| Revenue Growth | 48.64% | -2.18% | 18.13% | 21.36% | -13.65% | -1.75% | 22.54% | 8.89% | 63.66% | - |
| Gross Profit | 1.20 | -0.09 | 0.21 | -0.06 | -0.13 | 1.29 | 2.40 | 1.96 | 1.79 | 1.09 |
| Operating Income | -15.28 | -11.33 | -10.44 | -14.95 | -19.25 | -19.21 | -8.86 | -8.62 | -17.74 | -16.28 |
| Net Income | -15.24 | -11.37 | -10.50 | -14.97 | -19.12 | -19.21 | -8.82 | -7.15 | -17.79 | -19.03 |
| Shares Outstanding | 86.60 | 70.09 | 56.94 | 52.20 | 47.12 | 36.08 | 20.93 | 15.01 | 14.25 | 10.40 |
| Earnings Per Share | -0.18 | -0.16 | -0.20 | -0.29 | -0.41 | -0.53 | -0.42 | -0.48 | -1.25 | -1.83 |
| Operating Cash Flow | -12.97 | -9.37 | -8.13 | -13.96 | -18.37 | -16.81 | -8.22 | -10.40 | -15.58 | -20.94 |
| Capital Expenditures | -0.13 | -0.11 | -0.06 | -1.26 | -1.06 | -0.26 | -0.32 | -0.01 | -0.10 | -0.18 |
| Free Cash Flow | -13.10 | -9.48 | -8.19 | -15.22 | -19.42 | -17.07 | -8.55 | -10.41 | -15.68 | -21.11 |
| Cash & Equivalents | 11.70 | 9.36 | 5.54 | 5.24 | 18.64 | 22.97 | 29.50 | 8.01 | 22.48 | 22.91 |
| Total Debt | 1.29 | 1.48 | 1.67 | 1.85 | - | 1.11 | 1.11 | 1.11 | 7.00 | 12.00 |
| Net Cash / Debt | 10.41 | 7.88 | 3.87 | 3.39 | 18.64 | 21.86 | 28.40 | 6.90 | 15.48 | 10.91 |
| Assets | 13.83 | 11.41 | 7.50 | 8.02 | 20.96 | 24.17 | 30.64 | 8.63 | 23.11 | 24.04 |
| Liabilities | 5.09 | 4.26 | 4.09 | 4.26 | 3.41 | 4.92 | 3.87 | 3.97 | 12.75 | 19.42 |
| Book Value | 8.74 | 7.15 | 3.41 | 3.76 | 17.55 | 19.26 | 26.77 | 4.67 | 10.36 | 4.62 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aspira Women's Health, Inc. |
| Country |
United States |
| Employees |
52 |
| CEO |
Valerie Barber Palmieri |
Stock Information
| Ticker Symbol |
AWH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: AWH |
Description
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.